Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CASI Pharmaceuticals ( (CASI) ) just unveiled an announcement.
CASI Pharmaceuticals disclosed on February 25, 2026 that it received a Nasdaq Hearings Panel decision dated February 23, 2026 to delist its securities for failing to meet continued listing requirements, with trading to be suspended at the market open on February 26, 2026. The company will not appeal the ruling and expects its shares to transition to quotation on the OTC Markets platform, though it warned there is no assurance of an active over-the-counter market, while emphasizing the Nasdaq delisting is not expected to materially affect its underlying operations.
The move marks a setback for CASI’s capital markets profile and could reduce liquidity and visibility for existing shareholders, even as the company continues to advance its CID-103 clinical programs in transplant rejection and autoimmune indications. For investors and partners, the shift off a major exchange heightens market-access and trading risk but does not alter the stated development trajectory of CID-103 or the company’s ongoing regulatory and clinical activities.
The most recent analyst rating on (CASI) stock is a Hold with a $0.96 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.
The score is primarily weighed down by poor financial performance (declining revenue, ongoing losses, negative and worsening free cash flow, and very high leverage). Technicals are somewhat improved in the short term but remain weak versus longer-term trend levels, while valuation is difficult to support due to negative earnings and no dividend yield data.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing CID-103, a fully human IgG1 anti-CD38 monoclonal antibody targeting organ transplant rejection and autoimmune diseases. The company holds exclusive global rights to CID-103, has secured Chinese Phase 1/2 and U.S. Phase 1 regulatory clearances in chronic active renal allograft antibody-mediated rejection, and is recruiting patients in a Phase 1 trial in immune thrombocytopenia while exploring high-concentration subcutaneous formulations.
Average Trading Volume: 37,400
Technical Sentiment Signal: Sell
Current Market Cap: $12.39M
See more insights into CASI stock on TipRanks’ Stock Analysis page.